CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-06 | Kaye Edward M. MD Director | Sale 10b5-1 | −6,757 | $60.00 | $405K | 9,778 |
| 2025-10-01 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $55.05 | $275K | 368,108 |
| 2025-09-30 | Kaye Edward M. MD Director | Sale 10b5-1 | −6,695 | $55.08 | $369K | 16,535 |
| 2025-09-23 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,610 |
| 2025-09-23 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $49.28 | $99K | 140,610 |
| 2025-09-23 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 5,105 | ||
| 2025-09-15 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $49.77 | $249K | 373,108 |
| 2025-09-09 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,610 |
| 2025-09-09 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $51.29 | $103K | 140,610 |
| 2025-09-09 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 7,105 | ||
| 2025-09-02 | Kaye Edward M. MD Director | Sale 10b5-1 | −6,756 | $50.00 | $338K | 23,230 |
| 2025-09-02 | Harrington Robert Arthur Director | Sale 10b5-1 | −2,150 | $48.67 | $105K | 20,493 |
| 2025-09-02 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $48.76 | $244K | 378,108 |
| 2025-08-19 | Daly James M Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +27,450 | 27,450 | ||
| 2025-08-19 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,610 |
| 2025-08-19 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $38.31 | $77K | 140,610 |
| 2025-08-19 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 9,105 | ||
| 2025-08-15 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $38.42 | $192K | 383,108 |
| 2025-08-05 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,610 |
| 2025-08-05 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $36.34 | $73K | 140,610 |
Page 17 of 22 · 429 trades